1. Home
  2. UIS vs AKBA Comparison

UIS vs AKBA Comparison

Compare UIS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unisys Corporation New

UIS

Unisys Corporation New

SELL

Current Price

$2.21

Market Cap

208.5M

Sector

Technology

ML Signal

SELL

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UIS
AKBA
Founded
1942
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.5M
248.3M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
UIS
AKBA
Price
$2.21
$0.80
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
★ $4.81
$3.92
AVG Volume (30 Days)
587.8K
★ 6.0M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
N/A
★ N/A
Revenue
★ $1,950,100,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.84
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.97
$0.81
52 Week High
$4.98
$3.19

Technical Indicators

Market Signals
Indicator
UIS
AKBA
Relative Strength Index (RSI) 32.99 35.17
Support Level $2.14 N/A
Resistance Level $2.61 $0.98
Average True Range (ATR) 0.09 0.04
MACD 0.01 -0.01
Stochastic Oscillator 13.55 11.57

Price Performance

Historical Comparison
UIS
AKBA

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: